PT2177223E - Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes - Google Patents

Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes Download PDF

Info

Publication number
PT2177223E
PT2177223E PT09172828T PT09172828T PT2177223E PT 2177223 E PT2177223 E PT 2177223E PT 09172828 T PT09172828 T PT 09172828T PT 09172828 T PT09172828 T PT 09172828T PT 2177223 E PT2177223 E PT 2177223E
Authority
PT
Portugal
Prior art keywords
homoharringtonine
sti571
protein kinase
kinase inhibitors
use according
Prior art date
Application number
PT09172828T
Other languages
English (en)
Portuguese (pt)
Inventor
Julie Blanchard
Francois-Xavier Mahon
Jean-Pierre Robin
Frederick Maloisel
Herve Maissonneuve
Original Assignee
Chemgenex Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgenex Pharmaceuticals Ltd filed Critical Chemgenex Pharmaceuticals Ltd
Publication of PT2177223E publication Critical patent/PT2177223E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT09172828T 2001-09-05 2002-09-05 Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes PT2177223E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31696701P 2001-09-05 2001-09-05

Publications (1)

Publication Number Publication Date
PT2177223E true PT2177223E (pt) 2012-05-23

Family

ID=23231501

Family Applications (2)

Application Number Title Priority Date Filing Date
PT09172828T PT2177223E (pt) 2001-09-05 2002-09-05 Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes
PT02772653T PT1443933E (pt) 2001-09-05 2002-09-05 Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, utilizando homoharringtonina isoladamente ou em combinação com outros agentes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02772653T PT1443933E (pt) 2001-09-05 2002-09-05 Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, utilizando homoharringtonina isoladamente ou em combinação com outros agentes

Country Status (12)

Country Link
US (1) US6987103B2 (https=)
EP (2) EP1443933B1 (https=)
JP (2) JP4794816B2 (https=)
AT (2) ATE548041T1 (https=)
AU (1) AU2002337410A1 (https=)
CA (1) CA2459822C (https=)
CY (2) CY1109799T1 (https=)
DE (1) DE60234708D1 (https=)
DK (2) DK2177223T3 (https=)
ES (2) ES2383771T3 (https=)
PT (2) PT2177223E (https=)
WO (1) WO2003020252A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
ES2400375T3 (es) * 2006-04-07 2013-04-09 Novartis Ag Combinación que comprende A) un compuesto de pirimidilaminobenzamida y B)un inhibidor de cinasa THR315LLE
EP2049096A4 (en) * 2006-08-02 2012-05-09 Univ South Florida METHOD FOR TREATING CHRONIC MYELOGENIC LEUKEMIA CELLS
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
EP2229160A1 (en) * 2007-12-07 2010-09-22 ChemGenex Pharmaceuticals, Inc. Leukemic stem cell ablation
JP5617175B2 (ja) 2008-04-17 2014-11-05 富士電機株式会社 ワイドバンドギャップ半導体装置とその製造方法
AU2012275190B2 (en) * 2011-06-29 2016-05-19 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders

Also Published As

Publication number Publication date
AU2002337410A1 (en) 2003-03-18
JP4794816B2 (ja) 2011-10-19
US20040019036A1 (en) 2004-01-29
JP2005508896A (ja) 2005-04-07
EP2177223B1 (en) 2012-03-07
PT1443933E (pt) 2010-01-27
JP2009102408A (ja) 2009-05-14
WO2003020252A3 (en) 2003-06-19
ATE451106T1 (de) 2009-12-15
DE60234708D1 (de) 2010-01-21
US6987103B2 (en) 2006-01-17
ES2383771T3 (es) 2012-06-26
CA2459822C (en) 2013-01-29
EP2177223B9 (en) 2012-10-31
CY1109799T1 (el) 2014-09-10
ATE548041T1 (de) 2012-03-15
DK2177223T3 (da) 2012-04-10
EP1443933A2 (en) 2004-08-11
CY1112817T1 (el) 2016-02-10
WO2003020252A2 (en) 2003-03-13
HK1143732A1 (en) 2011-01-14
HK1067562A1 (en) 2005-04-15
EP1443933B1 (en) 2009-12-09
EP2177223A3 (en) 2010-05-19
CA2459822A1 (en) 2003-03-13
DK1443933T3 (da) 2010-01-25
EP2177223A2 (en) 2010-04-21
ES2334774T3 (es) 2010-03-16

Similar Documents

Publication Publication Date Title
PT2177223E (pt) Tratamento da leucemia mielóide crónica, resistente ou intolerante ao sti571, envolvendo a homoharringtonina isoladamente ou em combinação com outros agentes
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
JP2020528880A (ja) 併用がん療法
CN108883109A (zh) 用于治疗急性髓性白血病的联合疗法
US11622965B2 (en) Methods for treating lymphoid malignancies
JP2005508896A5 (https=)
KR20250167640A (ko) 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물
TW201834649A (zh) 癌症療法
JP2021063014A (ja) 白血病治療薬
MX2015006592A (es) Terapia de combinacion con volasertib.
WO2020022507A1 (ja) 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤
CN116323609A (zh) 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
KR20220003475A (ko) 3-케토아실 CoA 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
Ho et al. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes
HK1143732B (en) Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571
JP2020524681A (ja) 血液ガンのためのｍｃｌ−１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
ES2396468T3 (es) Composiciones para uso en el tratamiento del síndrome mielodisplástico
CN112533605A (zh) 用于治疗癌症的组合疗法
CN116390735A (zh) 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
HK40040825A (zh) 用於治疗癌症的组合疗法
TWI674094B (zh) 治療或緩解慢性骨髓性白血病用之醫藥組合物
WO2022217068A1 (en) Methods of treatment for leukemia
Furusaka et al. CAP therapy for advanced, recurrent and/or metastatic malignant tumors of the head and neck
Carlson HHT on Fast Track to STI571 Combo Trials
HK1067562B (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents